Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00267358 · ClinicalTrials.gov registry record · Phase 2
Placebo Controlled, Randomized Safety and Efficacy Study of RC-1291 in Cancer Anorexia/Cachexia.
A Phase 2 study, sponsored by Helsinn Therapeutics (U.S.).
- Completed
- Registry status
- Phase 2
- Development phase
NCT00267358 is a Phase 2 study that has completed, run by Helsinn Therapeutics (U.S.).
The verdict
NCT00267358, a Phase 2 study, has completed, sponsored by Helsinn Therapeutics (U.S.).
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
Anorexia and cachexia are devastating complications in late-stage cancer patients and is strongly associated with mortality in these patients. Activation of Ghrelin receptors have been demonstrated to stimulate appetite. RC-1291 HCl, by virtue of its ghrelin like activity and Growth Hormone releasing effects may have a dual role in the reversal of cancer induced anorexia and cachexia. This placebo controlled study will evaluate the safety and efficacy of RC-1291 HCl in cancer patients with anorexia and cachexia.
Interventions
- DRUG Placebo
- DRUG RC-1291 HCl
Trial Details
| Field | Value |
|---|---|
| Start Date | 2005-11 |
| Est. Completion | 2006-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00267358
The ClinicalTrials.gov registry entry for NCT00267358 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Helsinn Therapeutics (U.S.), which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00267358 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00267358 about?
NCT00267358 is a clinical study titled "Placebo Controlled, Randomized Safety and Efficacy Study of RC-1291 in Cancer Anorexia/Cachexia.". Anorexia and cachexia are devastating complications in late-stage cancer patients and is strongly associated with mortality in these patients. Activation of Ghrelin receptors have been demonstrated to stimulate appetite. RC-1291 HCl, by virtue of its ghrelin like activity and Growth Hormone releasin...
What is the current status of trial NCT00267358?
This trial is currently completed. It is a Phase 2 study. The study started on 2005-11. Estimated completion is 2006-10.
What interventions are being tested in trial NCT00267358?
The interventions under investigation include: Placebo (DRUG), RC-1291 HCl (DRUG).
Who is sponsoring clinical trial NCT00267358?
This trial is sponsored by Helsinn Therapeutics (U.S.), which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.